Downregulation of the Ornithine Decarboxylase/polyamine System Inhibits Angiotensin-induced Hypertrophy of Cardiomyocytes Through the NO/cGMP-dependent Protein Kinase Type-I Pathway
暂无分享,去创建一个
Hongzhu Li | Yajun Zhao | Yu-hui Xi | Li-na Wang | Yan Lin | Ji-Cheng Liu | Xiao-Jie Zhang | Guang-Wei Li | Li-Na Wang | Yu-Hui Xi | Hong-Zhu Li | Ya-Jun Zhao | Chang-Qing Xu | Jicheng Liu | Yan Lin | Guang-wei Li | Xiaojie Zhang | Chang‐qing Xu
[1] L. Ignarro,et al. Potential cardioprotective actions of no-releasing aspirin , 2002, Nature Reviews Drug Discovery.
[2] L. Shantz,et al. Targeted overexpression of ornithine decarboxylase enhances beta-adrenergic agonist-induced cardiac hypertrophy. , 2001, The Biochemical journal.
[3] H. Drexler,et al. Single L-type Ca(2+) channel regulation by cGMP-dependent protein kinase type I in adult cardiomyocytes from PKG I transgenic mice. , 2003, Cardiovascular research.
[4] T. Patel,et al. Polyamine depletion arrests cell cycle and induces inhibitors p21(Waf1/Cip1), p27(Kip1), and p53 in IEC-6 cells. , 1999, The American journal of physiology.
[5] L. Shantz,et al. Targeted overexpression of ornithine decarboxylase enhances β-adrenergic agonist-induced cardiac hypertrophy , 2001 .
[6] N. Parameswaran,et al. Adrenomedullin Increases AP-1 Expression in Rat Mesangial Cells via Activation of Protein Kinase-A and p38 MAPK , 2003, Cellular Physiology and Biochemistry.
[7] J. Molkentin,et al. Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death. , 2002, Circulation research.
[8] D. Welch,et al. Influence of polyamines on in vitro and in vivo features of aggressive and metastatic behavior by human breast cancer cells , 2004, Clinical & Experimental Metastasis.
[9] Guangping Chen,et al. All-trans retinoic acid induction of sulfotransferases. , 2005, Basic & clinical pharmacology & toxicology.
[10] Y. Yazaki,et al. Control of cardiac gene expression by mechanical stress. , 1993, Annual review of physiology.
[11] Hongzhu Li,et al. L-arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways. , 2008, Basic & clinical pharmacology & toxicology.
[12] Qin M. Chen,et al. Molecular mechanisms of cardiac hypertrophy induced by toxicants , 2007, Cardiovascular Toxicology.
[13] F. Hofmann,et al. cGMP-Dependent Protein Kinase I Mediates the Negative Inotropic Effect of cGMP in the Murine Myocardium , 2002, Circulation research.
[14] G. Dorn,et al. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.
[15] L. Ignarro,et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[16] A. Hughes,et al. Role of polyamines in hypertension induced by angiotensin II. , 1995, Cardiovascular research.
[17] Rui Wang,et al. Expression of voltage-dependent K+ channel genes in mesenteric artery smooth muscle cells. , 1999, American journal of physiology. Gastrointestinal and liver physiology.
[18] J. Frost,et al. Mitogen-activated protein kinases mediate changes in gene expression, but not cytoskeletal organization associated with cardiac muscle cell hypertrophy , 1994, The Journal of cell biology.
[19] J. Sadoshima,et al. The cellular and molecular response of cardiac myocytes to mechanical stress. , 1997, Annual review of physiology.
[20] Yen-Ling Chen,et al. Nitric Oxide Inhibits Endothelin-1-Induced Cardiomyocyte Hypertrophy through cGMP-mediated Suppression of Extracellular-Signal Regulated Kinase Phosphorylation , 2005, Molecular Pharmacology.
[21] D. Mann,et al. Mechanisms and models in heart failure: A combinatorial approach. , 1999, Circulation.
[22] K. Chien,et al. Signaling pathways for cardiac hypertrophy and failure. , 1999, The New England journal of medicine.
[23] A. Pegg,et al. Polyamine metabolism and its importance in neoplastic growth and a target for chemotherapy. , 1988, Cancer research.
[24] H. Guo,et al. Multiple polyamine regulatory pathways control compensatory cardiovascular hypertrophy in coarctation hypertension. , 1997, Clinical and experimental hypertension.
[25] H. Drexler,et al. Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[26] J. Sadoshima,et al. Critical Role of the AT1 Receptor Subtype , 2005 .
[27] T. Menges,et al. Nitric oxide and polyamine pathway-dependent modulation of neutrophil free amino- and α-keto acid profiles or host defense capability , 2006, Amino Acids.
[28] J. Bronzwaer,et al. Nitric oxide's role in the heart: control of beating or breathing? , 2004, American journal of physiology. Heart and circulatory physiology.
[29] M. Salvi,et al. Effects of polyamines on mitochondrial Ca(2+) transport. , 2004, Biochimica et biophysica acta.
[30] E. Olson,et al. Decoding calcium signals involved in cardiac growth and function , 2000, Nature Medicine.